Jeff Aronin recognizes Evozyne for unlocking the potential of novel proteins

Evozyne, a portfolio company of Paragon Biosciences, announced that a peer-reviewed publication in the journal Science demonstrates successful use of its world-class molecular engineering technology to create never-before-seen proteins with exceptionally advanced functionality. The Chicago-based company has enormous potential to enable innovation and growth across multiple industries including industrial, agricultural, energy, biopharmaceutical, and environmental.

“At Paragon, we create and support focused visionary companies to accelerate life science innovations,” said Jeff Aronin, founder, chairman and chief executive officer of Paragon Biosciences. “Through its novel application of synthetic biology, Evozyne is addressing human and societal challenges in ways that were previously unimaginable.”

Read the press release here.

The Science paper “An evolution-based model for designing chorismate mutase enzymes” is available here.